Search Results - "Jarlot, Camille"

Management of cytomegalovirus infection in inflammatory bowel diseases by Pillet, Sylvie, Pozzetto, Bruno, Jarlot, Camille, Paul, Stéphane, Roblin, Xavier

“…Abstract Cytomegalovirus is a deoxyribonucleic acid virus that infects a large part of the human population; after primary infection, it develops a latent…”
Get full text

Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months by Williet, Nicolas, Boschetti, Gilles, Fovet, Marion, Di Bernado, Thomas, Claudez, Pierre, Del Tedesco, Emilie, Jarlot, Camille, Rinaldi, Leslie, Berger, Anne, Phelip, Jean-Marc, Flourie, Bernard, Nancey, Stéphane, Paul, Stéphane, Roblin, Xavier

“…Background & Aims We investigated whether serum trough levels of vedolizumab, a humanized monoclonal antibody against integrin α4β7, during the induction phase…”
Get full text

Infliximab Does Not Worsen Outcomes During Flare-ups Associated with Cytomegalovirus Infection in Patients with Ulcerative Colitis by Pillet, Sylvie, Jarlot, Camille, Courault, Mathilde, Del Tedesco, Emilie, Chardon, Renaud, Saint-Sardos, Pierre, Presles, Emilie, Phelip, Jean-Marc, Berthelot, Philippe, Pozzetto, Bruno, Roblin, Xavier

“…Immunosuppressive therapies used for treating ulcerative colitis are known to favor chronic and latent viral diseases. This study aimed at evaluating…”
Get full text

Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease by Roblin, Xavier, Duru, Gerard, Williet, Nicolas, Del Tedesco, Emilie, Cuilleron, Murielle, Jarlot, Camille, Phelip, Jean Marc, Boschetti, Gilles, Flourié, Bernard, Nancey, Stephane, Peyrin-Biroulet, Laurent, Paul, Stephane

“…The best noninvasive method predicting clinical relapse remains undetermined in infliximab (IFX)-treated patients with Crohn's disease. All patients with CD on…”
Get full text

Sa1940 Immunogenicity of Anti-TNF in IBD Patients Aged Over 60 Years by Paul, Stephane, Rinaldi, Leslie, Williet, Nicolas, Del Tedesco, Emilie, Jarlot, Camille, Genin, Christian, Phelip, Jean Marc, Depince, Anne, Roblin, Xavier

Get full text

Tu1236 Infliximab Trough Level Thresholds Vary Depending on the Efficacy Criterion Chosen in IBD Patients by Roblin, Xavier, Rinaudo-gaujous, Melanie, Jarlot, Camille, Deltedesco, Emilie, Phelip, Jean Marc, Clavel, Lea, Peyrin-Biroulet, Laurent, Paul, Stephane

Get full text

Sa1939 Serum Vedolizumab Assay at Week 6 Predicts Sustained Clinical Remission and Lack of Recourse to Optimisation in IBD by Paul, Stephane, Williet, Nicolas, Claudez, Pierre, Fauvet, Marion, Del Tedesco, Emilie, Jarlot, Camille, Phelip, Jean Marc, Genin, Christian, Depince, Anne, Roblin, Xavier

Get full text

693 Azathioprine Dose Reduction in Inflammatory Bowel Disease Patients on Combination Therapy: A Prospective Study by Del Tedesco, Emilie, Paul, Stephane, Marotte, Hubert, Jarlot, Camille, Williet, Nicolas, Phelip, Jean Marc, Peyrin-Biroulet, Laurent, Colombel, Jean-Frederic, Roblin, Xavier

Get full text

The level of epidermal growth factor receptors expression is correlated with the advancement of colorectal adenoma: validation of a surface biomarker by Williet, Nicolas, Petcu, Carmen Adina, Rinaldi, Leslie, Cottier, Michèle, Del Tedesco, Emilie, Clavel, Léa, Dumas, Olivier, Jarlot, Camille, Bouarioua, Nadia, Roblin, Xavier, Peoc'h, Michel, Phelip, Jean-Marc

“…Data about the expression of Epidermal Growth Factor Receptors (EGFRs) in colorectal adenomas remain scarce. 101 patients were enrolled including 53 controls…”
Get full text

Tu1304 Faecal Calprotectin Measurement and Infliximab Trough Levels Predict Therapeutic Evolution CD Patients in Clinical Remission by Roblin, Xavier, Duru, Gerard, Clavel, Lea, Rinaudo-gaujous, Melanie, Deltedesco, Emilie, Cuilleron, Muriel, Jarlot, Camille, Phelip, Jean Marc, Peyrin-Biroulet, Laurent, Paul, Stephane

Get full text